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ABSTRACT
Escape from apoptosis is one of the major hallmarks of cancer cells. The B-cell 
Lymphoma 2 (BCL-2) gene family encodes pro-apoptotic and anti-apoptotic proteins 
that are key regulators of the apoptotic process. Overexpression of the pro-survival 
member BCL-2 is a well-established mechanism contributing to oncogenesis and 
chemoresistance in several cancers, including lymphoma and leukemia. Thus, BCL-2 
has become an attractive target for therapeutic strategy in cancer, as demonstrated 
by the recent approval of ABT-199 (Venclexta™) in relapsed or refractory Chronic 
Lymphocytic Leukemia with 17p deletion. Here, we describe a novel orally bioavailable 
BCL-2 selective and potent inhibitor called S55746 (also known as BCL201). S55746 
occupies the hydrophobic groove of BCL-2. Its selectivity profile demonstrates 
no significant binding to MCL-1, BFL-1 (BCL2A1/A1) and poor affinity for BCL-XL. 
Accordingly, S55746 has no cytotoxic activity on BCL-XL-dependent cells, such as 
platelets. In a panel of hematological cell lines, S55746 induces hallmarks of apoptosis 
including externalization of phosphatidylserine, caspase-3 activation and PARP 
cleavage. Ex vivo, S55746 induces apoptosis in the low nanomolar range in primary 
Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma patient samples. Finally, 
S55746 administered by oral route daily in mice demonstrated robust anti-tumor 
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efficacy in two hematological xenograft models with no weight lost and no change 
in behavior. Taken together, these data demonstrate that S55746 is a novel, well-
tolerated BH3-mimetic targeting selectively and potently the BCL-2 protein.
INTRODUCTION
Apoptosis is a tightly controlled and evolutionarily 
conserved process of programmed cell death that is 
crucial for tissue homeostasis [1]. Evasion of apoptosis is 
critical for tumor development as well as maintenance and 
represents an almost universal hallmark of cancer which, 
importantly, also underpins resistance to diverse anti-
cancer treatments [2]. BCL-2 family proteins are crucial 
regulators of the mitochondrial apoptotic pathway and 
are characterized by the presence of up to four conserved 
BCL-2 Homology (BH) domains. BCL-2, the first 
identified member of this family was originally discovered 
as part of the t(14;18) chromosomal translocation which 
occurs in human B cell lymphomas [3, 4]. BCL-2 family 
proteins are divided into 3 functionally distinct groups: 
(i) the pro-survival proteins (BCL-2, BCL-XL, BCL-W, 
MCL-1 and BFL-1/BCL2A1/A1), (ii) the multi-BH 
domain cell death effectors (BAX, BAK, BOK) and 
(iii) the BH3-only apoptosis initiators (e.g. BIM, BAD, 
NOXA) [5]. Dysregulation of the BCL-2 family altering 
the balance between pro-survival and pro-death members 
provides a common mechanism by which cancer cells 
acquire a survival advantage [6]. Dynamic interactions 
between members of BCL-2 family subgroups, involving 
binding of the BH3 domain of the pro-apoptotic members 
to a groove at the surface of the pro-survival proteins, 
control commitment to apoptosis [7]. Following activation 
by cellular stress, BH3-only proteins initiate apoptosis 
by inhibiting the pro-survival BCL-2 proteins [8] and 
potentially by directly activating BAX and BAK [9]. The 
subsequent activation and oligomerization of the death 
effectors BAX and BAK result in mitochondrial outer 
membrane permeabilization and apoptosis. 
The pro-survival BCL-2 members exert their function 
by sequestering pro-apoptotic members through binding to 
their BH3 domains. Inhibiting these intracellular protein-
protein interactions is therefore an attractive strategy to 
target the aberrant survival of cancer cells caused by BCL-2 
family dysregulation [10]. ABT-737, which was discovered 
using structure-based drug design, targets BCL-2, BCL-XL 
and BCL-W and was the first example of an inhibitor of the 
pro-survival BCL-2 members demonstrating druggability 
of such targets [11]. Encouraging clinical activity against 
lymphoid malignancies thought to be BCL-2 dependent 
were observed in early trials with Navitoclax (ABT-263), 
the orally bioavailable analog of ABT-737 [12, 13, 14]. 
However, as BCL-XL has a crucial survival function 
in circulating platelets [15], Navitoclax induced a rapid 
thrombocytopenia due to its inhibition of BCL-XL, which 
limited its clinical utility. It was therefore hypothesized 
that a BCL-2 selective inhibitor should exhibit limited 
thrombocytopenia while maintaining antitumor activity 
in BCL-2 dependent lymphoid malignancies. Subsequent 
rational drug discovery research efforts led to the 
development of Venclexta™ (ABT-199), the first orally 
active BCL-2 selective (BCL-XL-sparing) inhibitor [16] 
that has been recently approved in high risk patients with 
relapsed or refractory Chronic Lymphocytic Leukemia 
(CLL) [17]. Here we describe S55746 (also known as 
BCL201), a novel, orally active BCL-2 specific inhibitor 
that has a partially overlapping but distinct BCL-2 
hydrophobic groove binding mode compared to ABT-199. 
S55746, currently in phase I clinical trials in heamatological 
malignancies (Trials registration ID: NCT02920697, 
NCT02920541 and NCT02603445) displays all the 
hallmarks of a BCL-2 specific BH3-mimetic and exhibits 
robust antitumor activity in BCL-2 dependent lymphoid 
tumor xenograft models while sparing platelets.
RESULTS
S55746 is a selective inhibitor of BCL-2 
Starting from a moderately active literature 
compound [18, 19] and using a structure-based drug design 
approach, S55746 was developped as described in Le 
Diguarher et al. 2013 [20] (Figure 1A and Supplementary 
Materials and Methods). Fluorescence polarization (FP) 
data, using Fluorescent-PUMA as a binder, demonstrates 
that S55746 is a potent inhibitor of BCL-2 (Ki = 1.3 nM). 
The selectivity of S55746 for BCL-2 versus BCL-XL 
ranges from ~70 to 400 folds depending on the assay used 
(Table 1). No significant binding to MCL-1 and BFL-
1 was observed (Table 1). S55746 occupies the region 
typically referred to as S1/2/3 in contrast to the ABT-
199 analog [16], which occupies a greater portion of the 
protein surface area including S2/3/4/5. S55746 adopts 
essentially the same binding mode as described in Porter 
et al. 2009 [18]. S55746 forms a single hydrogen bond to 
the backbone carbonyl of residue A149 (Figure 1B) buried 
deep into S2. The size-independent enthalpic efficiency 
(0.83) for S55746 binding to BCL-2 is suggestive of 
optimal polar and Van der Waal’s interactions, indicative 
of highly specific binding (Figure 1B) [21].
S55746 induces cell death selectively 
The selectivity and potency of S55746 was firstly 
evaluated in the well-described BCL-2-dependent acute 
lymphoblastic leukemia (ALL) RS4;11 cell line, which 
express high levels of BCL-2 but low levels of BCL-XL 
[22] (Figure 2A, left panel). S55746 potently induces 
RS4;11 cell killing after 72 h of treatment with an IC50 
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of 71.6 nM (Figure 2A, right panel and Supplementary 
Figure 1A). Interestingly, S55746 exhibits a much weaker 
activity in H146 (IC50 1.7 µM), a BCL-XL-dependent 
cell line [23], which expresses a low level of BCL-
2 and high level of BCL-XL (Figure 2A, left panel) 
whereas ABT-263, which targets BCL-2 and BCL-XL 
[14], induces equivalent cell killing in both RS4;11 and 
H146 (41.5 nM and 49.7 nM, respectively; Figure 2A, 
right panel and Supplementary Figure 1B). Of note, the 
BCL-2 selective inhibitor ABT-199 displays identical 
selectivity profile than S55746 in these two cell lines. 
Selective targeting of BCL-2 by S55746 was confirmed 
by co-immunoprecipitation experiments, which showed 
a concentration-dependent disruption of the BCL-2/
BAX complex in RS4;11 cells following treatment with 
increasing concentrations of S55746 (Figure 2B). In BCL-
2-overexpressing HeLa cells, S55746 affects BCL-2/BAX 
complex without any significant effect on the BCL-XL/
BAX complex in BCL-XL-overexpressing HeLa cells 
(Figure 2C, left panel). In contrast, ABT-263 was shown to 
disrupt both BCL-2/BAX and BCL-XL/BAX complexes 
(Figure 2C, right panel). 
S55746 selectively induces apoptosis through 
BCL-2 inhibition in a BAX/BAK-dependent 
manner
S55746 rapidly induced apoptosis in a concentration 
dependent-manner, as monitored by externalization of 
phosphatidylserine (PS+ cells) in RS4;11 cells (Figure 
3A). Cleavage of caspase-3 and Poly ADP-ribose 
polymerase (PARP) was also observed upon treatment 
by S55746 in a concentration dependent manner in the 
same cellular model (Supplementary Figure 1C and 
1D, respectively). S55746-induced apoptosis in RS4;11 
is mediated in part by the BAX effector protein since 
PARP cleavage (Figure 3B) is markedly inhibited in 
BAX-deficient RS4;11 cells, generated using a shRNA-
based approach compared to control RS4;11 cells upon 
treatment with increasing concentration of S55746. The 
sensitivity of BAX-deficient RS4;11 cells was strongly 
reduced compared to control RS4;11 (≈ 50-fold, IC50 = 2.7 
µM versus 0.057 µM, Figure 3C). The dependence of the 
killing activity of S55746 on BAX and BAK was further 
confirmed by CRISPR/Cas9 genome editing in the THP-1 
AML cell line (Supplementary Figure 2).
To further assess the selectivity of S55746 on 
apoptosis induction, S55746 was tested in the IL3-
dependent murine pro-B lymphocytic FL5.12 cell line 
expressing either BCL-2 or BCL-XL as a required protein 
for cell survival in the absence of IL-3 [24]. Upon IL-3 
withdrawal, increasing concentrations of ABT-737, an 
analogue inhibitor of ABT-263 that targets BCL-2 and 
BCL-XL, efficiently induced apoptosis, as illustrated by 
the increasing percentage of PS+ cells in either BCL-2 or 
BCL-XL-dependent FL5.12 cells (Figure 3D, left panel). 
However, S55746 was shown to strongly induce apoptosis 
in BCL-2-dependent FL5.12 cells with a minor effect in 
BCL-XL-dependent FL5.12 cells (Figure 3D, right panel). 
Of note is that isolated platelets from healthy volunteers, 
known to be strictly dependent on BCL-XL for survival 
[15], were totally insensitive to S55746 (EC50 > 3 µM) 
in contrast to ABT-737 which strongly induced apoptosis 
(EC50 = 0.03 µM; Figure 3E). Altogether, these data 
demonstrate that S55746 kills cancer cells through on-target 
activity, meaning activation of a BAX/BAK-dependent 
mitochondrial apoptotic pathway by direct inhibition of the 
BCL-2 pro-survival protein.
Figure 1: Chemical structure and binding mode of S55746. (A) Chemical structure of S55746. (B) Superposition of S55746 
(green sticks) and ABT-199 analogue from PDB 4MAN (orange lines) X-ray crystal structures. Ala149 is highlighted (space-filling 
spheres) and the hydrogen bond from S55746 phenol to backbone carbonyl of Ala149 is shown (cyan dashed line). The key S1 and S2 
binding pockets are shown as translucent yellow surfaces.By comparison with the ABT-199 analogue it can be seen that S55746 forms a 
compact structure that only accesses pockets S1/S2/S3 and not S4/S5. Image was prepared using Pymol.
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Activity of S55746 in hematological cell 
malignancies in vitro and ex vivo
Activity of S55746 was assessed in a panel of non-
Hodgkin lymphoma cell lines including Diffuse Large 
B-Cell Lymphoma (DLBCL; Figure 4A), Mantle Cell 
Lymphoma (MCL; Figure 4B) and Burkitt Lymphoma 
(BL; Figure 4C). After 72 h of treatment, we found that six 
out of eleven DLBCL cell lines tested had an IC50 below 
1 µM. Two MCL cell line out of five tested displayed 
an IC50 below 1 µM for S55746. In contrast, all Burkitt 
lymphoma cell lines tested had an IC50 above 10 µM for 
S55746. Cellular results for the BCL-2 selective inhibitor 
ABT-199 are shown for comparison (Figure 4).
Chronic Lymphocytic Leukemia (CLL) cells are 
highly dependent on BCL-2 expression for survival 
[25]. Efficacy of S55746 was evaluated in primary CLL 
cells freshly isolated from 7 patients (Supplementary 
Table 1). S55746 caused rapid induction of apoptosis, 
reflected by the presence of phosphatidylserine positive 
cells. All primary CLL cells tested had an EC50 in a low 
nanomolar range (from 4.4 to 47.2 nM following 4 hours 
of treatment; Figure 5A, top panel and Supplementary 
Table 1). In two representative CLL patient samples, 
S55746 induced characteristic ultrastructural changes 
of apoptosis such as chromatin condensation (data 
not shown) in addition to extensive processing of 
caspase-9 and caspase-3 as well as cleavage of PARP 
(Figure 5A, lower panel). All these data are consistent 
with activation of the intrinsic apoptotic pathway in CLL 
cells by S55746. In contrast to the data obtained on cell 
lines (Figure 4B), S55746 potently induced apoptosis in 
primary MCL cells with EC50 ranging from 2.5 to 110 
nM following 24h of S55746 treatment (Figure 5B and 
Supplementary Table 2). Of note, ABT-199 has also been 
shown to be more potent on primary MCL cells versus 
MCL cell lines ; this potency shift is likely due to higher 
expression of BCL- XL in cell lines compare to primary 
cells [26]. Altogether, these data demonstrate that S55746 
is a potent BCL-2 inhibitor that induces apoptotic cell 
death in cells that are dependent on BCL-2 for survival.
S55746 is an effective agent that induces tumor 
regression in vivo
In order to confirm apoptosis induction by S55746 
in vivo, caspase-3 activity was assessed on RS4;11 
tumor xenografts 16 hours following single oral gavage 
treatment. Caspase-3 activity after S55746 treatment at 25 
and 100 mg/kg was about 11 and 28 times higher than 
in vehicle-treated animals, respectively. ABT-263 induced 
caspase-3 activation about 20 times higher than in vehicle-
treated group (Figure 6A). Consistent with the in vitro data 
(Figure 2 and Figure 3), S55746 treatment did not induce 
platelet loss in vivo at 25 and 100 mg/kg, while a strong 
decrease of platelet counts was observed upon treatment 
with ABT-263 at 100 mg/kg (Figure 6B).
Antitumor activity of S55746 was then evaluated 
in RS4;11 and Toledo models, two models that display 
different in vitro sensitivities towards S55746 (71.6 nM 
in RS4;11 (Figure 2A, right panel) vs 401 nM in Toledo 
(Figure 4A)). In RS4;11 bearing SCID mice, daily oral 
gavage treatment of S55746 for 7 consecutive days 
induced significant anti-tumor activity compared to 
untreated animals (p < 0.05 at 25 mg/kg and p < 0.001 at 
50 and 100 mg/kg). This response increased in magnitude 
and in durability in a dose dependent manner (Figure 6C). 
Seventeen days after beginning of treatment at 25 mg/kg, 
50 mg/kg and 100 mg/kg, tumor growth inhibition was 
67.1, 16.3 and −93.8 T/C respectively, with complete 
regression observed in all animals treated at 100 mg/kg 
(Supplementary Figure 3A and Supplementary Table 3).
Efficacy of S55746 was also assessed in Toledo 
bearing mice treated by oral gavage five times a week 
for 3 weeks at 200 and 300 mg/kg and compared to 
ABT-199 at 200 mg/kg (Figure 6D). After 21 days of 
treatment, S55746 induced a significant tumor growth 
inhibition either at 200 or 300 mg/kg (13% and 2% T/C, 
respectively; p < 0.05; Supplementary Table 4). In this 
model, S55746 and ABT-199 showed similar anti-tumor 
efficacy (Figure 6D). Individual data at day 21 post-
treatment are presented in Supplementary Figure 3B. 
Interestingly, body weight did not significantly differ in 
all treatment groups compared to the vehicle control group 
Table 1: Associated affinity and selectivity data of ABT-263, S55746 and ABT-199
FP_BCL-
2_KI (M)
FP_BCL-
XL_KI (M) FP_MCL-1 (M)
FP_BFL-1 
(M)
ITC_BCL-
2_KD (M) ∆H (kcal/mol) N (sites)
ITC_BCL-
XL_KD (M)
SPR AIS_BCL-2_ 
KD (M)
ABT-263 4.5E-09 3.5E-09 9.4%@10E-06 NT 3.7E-09 –13.1 0.8 2.9E-09 2.1E-09
S 55746 1.3E-09 5.2E-07 4.3%@30E-06 4.5%@30E-06 7.4%@5E-06 2.47E-09 –13.5 1.1 1.86E-07 3.9E-09
ABT-199 1.2E-09 4.9E-08 14.9%@30E-06 11.8%@30E-06 6.4%@3E-05 ND –12.1 1.1 2.1E-08 2.6E-10
The KI were determined by Fluorescence polarisation and KD by direct binding SPR. X%@10E-05 means X% of inhibition at the maximal tested concentration (M). FP: 
Fluorescence Polarization; SPR AIS: Surface Plasmon Resonance Affinity In Solution; ITC: Isothermal Titration Calorimetry; ∆H : enthalpy delta. NT, not tested. ND, not 
determinable (too potent). Of note, bottom limit for the FP assay was 1.2 nM.
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Figure 2: S55746 is a potent and selective inhibitor of BCL-2. (A) Expression of BCL-2, BCL-XL, MCL-1, BAX and BAK 
was assessed by immunoblotting in H146 and RS4;11 cell lines. GAPDH was used as a loading control (left panel). Viability of H146 and 
RS4;11 cell lines after incubation with increasing concentration of either ABT-263 (open circles), S55746 (open triangles) or ABT-199 
(open squares) for 72 h. IC50 indicates concentration at which 50% of inhibition is reached. Mean and individual data of 3 independent 
experiments are shown (right panel). (B) Co-immunoprecipitation assay of RS4;11 cells treated with different concentrations of S55746 
or ABT-263 for 2 h. ‘−’ indicates that cells were treated with DMSO only. Cells were lysed after treatment and immunoprecipitated 
(IP) with anti-BCL-2 antibody. The cell lysates (input) and immunoprecipitates were analyzed by immunoblotting with BAX or BCL-2 
antibodies as indicated. (C) Co-immunoprecipitation assay of HeLa cells transfected with plasmids expressing Flag-tagged BCL-2 or 
Flag-tagged BCL-XL as indicated. Cells were treated with different concentrations of S55746 or ABT-263 for 2 h. ‘−’ indicates that cells 
were treated with DMSO only. Cells were lysed after treatment and immunoprecipitated (IP) with anti-Flag antibody. The cell lysates 
(input) and immunoprecipitates were analyzed by immunoblotting with BAX or Flag antibodies as indicated. Representative blots of three 
independent experiments are shown.
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(Supplementary Figure 3C), even at doses up to 300 mg/
kg of S55746. Altogether, these data indicate that S55746 
is a highly efficacious and well-tolerated orally active 
BCL-2 inhibitor.
DISCUSSION
In the present study, we describe S55746, a novel 
bona fide BH3 mimetic compound which selectively 
inhibits BCL-2. Importantly, S55746 induces the critical 
hallmarks of the mitochondrial apoptosis pathway and 
kills BCL-2 dependent tumor cells in a BAX/BAK 
dependent manner. In vivo, S55746 is highly efficacious 
against BCL-2 dependent tumor models without causing 
platelet loss, in agreement with its strong selectivity for 
BCL-2 over BCL-XL, thus supporting its evaluation in 
clinical trials.
The role of BCL-2 in lymphoid malignancies is 
well recognized and BCL-2 overexpression found in 
such diseases is driven by multiple mechanisms. The 
Figure 3: S55746 induces apoptosis in a BAX-dependent manner. (A) Apoptosis induction in RS4;11 cells treated with S55746 
at the indicated concentration for 2 h. Cells were analyzed by flow cytometry for PI and annexin V-FITC labeling. Mean and individual 
points from two biological replicates are shown. ‘−’ indicates that cells were treated with DMSO only. (B) Expression of PARP and 
BAX assessed by immunoblotting in RS4;11 cells transduced with shRNA CT (control) or shRNA BAX upon treatment with increasing 
concentrations of S55746. Actin was used as a loading control. ‘−’ indicates that cells were treated with DMSO only. (C) Viability of 
RS4;11 cells transduced either with shRNA CT or shRNA BAX treated with increasing concentration of S55746 for 72 h. IC50 indicates 
concentration at which 50% of inhibition is reached. Mean and individual points from n = 3 biological replicates are shown. (D) FL5.12 
cells either expressing BCL-2 (filled circles, thick line) or BCL-XL (open triangles, dashed line) were treated with increasing concentration 
of either ABT-737 (left panel) or S55746 (right panel) for 24 h upon IL-3 withdrawal. Cells were then analyzed by flow cytometry for PI 
and annexin V-FITC labeling. Mean ± s.d. of 4 biological replicates are shown. (E) Isolated platelets from 4 healthy donors were treated 
with increasing concentrations of ABT-737 (squares, thick line) or S55746 (circles, dashed line) for 3 h. CD41-PE positive cells were then 
gated and analyzed for annexin V-FITC labeling. PS+: Phosphatidylserine positive cells. EC50: half maximal effective concentration. 
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t(14;18) chromosome translocation, bringing the BCL-
2 gene under the control of the immunoglobulin heavy 
chain enhancer is found in all B-cell follicular lymphomas 
[3, 4] and in approximately 30% of DLBCL [27] while 
BCL-2 gene amplification is commonly found in MCL 
and DLBCL [28]. BCL-2 is also overexpressed in both 
acute [29, 30] and chronic [31] leukemias where loss of 
microRNAs regulating BCL-2 expression are common 
[32, 33]. The clinical activity of Venclexta™ in these 
BCL-2 overexpressing hematological malignancies and 
its recent approval for patients with relapsed or refractory 
CLL with 17p deletion provide very strong clinical proof-
of-concept and seminal registration for drugs targeting the 
BCL-2 family. 
Figure 4: S55746 induces cell death in a panel of non-Hodgkin lymphoma cell lines. Viability of a panel of Diffuse Large 
B-Cell (DLBCL, A), Mantle Cell Lymphoma (MCL, B) and Burkitt lymphoma (BL, C) cell lines treated with increasing concentration 
of S55746 and ABT-199 for 72 h was determined using Cell Titer Glo. IC50 indicates concentration at which 50% of inhibition is reached. 
Mean and individual points from n = 3 biological replicates are shown. Origins of the cell lines are described in supplementary materials 
and methods.
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Figure 5: S55746 induces cell death in primary CLL and MCL cells. (A) Primary Chronic Lymphocytic Leukemia (CLL) cells 
freshly isolated from 7 patients were treated for 4 h with increasing concentrations of S55746. Cells were then analyzed by flow cytometry 
for PI and annexin V-FITC labeling. Individual curves of cells treated with S55746 are shown (top panel). CLL cells isolated from 2 patients 
were exposed to S55746 (3 nM) for 4 h. Total and cleaved caspase-3, caspase-9 and PARP were detected by immunoblotting using specific 
antibodies. Tubulin was used as a loading control (lower panel). (B) Primary Mantle Cell Lymphoma (MCL) cells freshly isolated from 8 
patients were cultured with increasing concentrations of S55746 for 24 h. Cells were then analyzed by flow cytometry for annexin V-FITC 
and CD19-APC positive labeling. Individual curves of cells treated with S55746 are demonstrated. PS+: Phosphatidylserine positive cells. 
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Target mutations causing resistance have been 
demonstrated with various high-affinity targeted therapies 
[34]. In the context of experimentally induced ABT-199 
resistance, BCL-2 mutations affecting its hydrophobic 
groove have been identified [35, 36]. The clinical relevance 
of these mutations remains unknown at this stage. Since 
ABT-199 and S55746 have different binding modes, one 
can theoretically speculate that mutation(s) in the BCL-2 
protein could cause resistance to one compound and not 
the other. Importantly, the pro-survival proteins MCL-1 
and BCL-XL have also emerged as resistance factors to 
the BCL-2 specific inhibitor ABT-199 [37]. The recent 
discovery of selective BCL-XL [38, 39] and MCL-1 
specific [40, 41] inhibitors is therefore of particular interest 
as these new specific BH3 mimetic compounds provide 
very promising strategies to overcome BCL-2 specific 
resistance mechanisms. The discovery of S55746, a new 
BCL-2 specific inhibitor, currently in phase I trials, could 
offer other opportunities to investigate the clinical utility of 
BCL-2 inhibition in the clinic.
Figure 6: S55746 inhibits xenograft growth in RS4;11 and Toledo models. (A and B) Female SCID mice were inoculated with 
1 × 107 RS4;11 cells and randomized 26 days after grafting. After randomization, mice were either not treated, or dosed once orally with 
vehicle, S55746 (25 mg/kg and 100 mg/kg) and ABT-263 (100 mg/kg). (A) Tumor samples were collected 16 h post dosing and analyzed 
for caspase-3 activity. Mean and individual data of caspase-3 activity fold increase over untreated group of 3 animals per treatment group 
are shown. (B) Platelet cells were counted 16 h post dosing. Mean and individual data of platelets counts of 3 animals per treatment group 
are shown. (C) Female SCID mice were inoculated with 1 × 106 RS4;11 cells and randomized 27 days after grafting. After randomization, 
mice were either not treated (black circles) or treated orally with S55746 every day for 7 consecutive days at 25 mg/kg (blue reverse 
triangles), 50 mg/kg (green squares) or 100 mg/kg (purple triangles). Mean tumor volumes with error bars depicting s.e.m. of 8 animals per 
treatment group are shown. One way ANOVA on day 17, followed by Dunnett post hoc comparison was performed and always compared to 
vehicle, (* p < 0.05; ***p < 0.001). (D) Female SCID mice were inoculated with 3 × 106 Toledo cells and randomized 24 days after grafting. 
After randomization, mice were either not treated (black circles) or treated orally five times a week with ABT-199 at 200 mg/kg (inverted 
red triangles) and S55746 at 200 mg/kg (blue squares) or 300 mg/kg (green triangles) for 3 weeks. Mean tumor volumes with error bars 
depicting s.e.m. of 6–7 animals per treatment group are shown. One way ANOVA on day 21, followed by Dunnett post hoc comparison 
was performed and always compared to vehicle, (* p < 0.05). 
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MATERIALS AND METHODS 
Human cells
Peripheral blood samples from CLL patients were 
obtained with informed patient consent and local ethical 
committee approval (UHL-09723). Peripheral blood 
mononuclear cells were purified using Histopaque (Sigma 
Aldrich, Dorset, United Kingdom) and cultured in RPMI 
1640 medium supplemented with 10% FCS and 2 mM 
L-glutamine (Life Technologies Inc, Paisley, United 
Kingdom) at 2 × 106 cells ml-1. Interphase fluorescence in 
situ hybridization (FISH) was performed for detection of 
17p13 deletion. Mantle cell lymphoma (MCL) primary cells 
were obtained after informed consent from MCL patients 
treated at the department of clinical hematology from the 
University Hospital of Nantes, France. Peripheral MCL 
cells from blood or pleural effusion, were purified after 
Ficoll-Hypaque separation with immuno-magnetic anti-
CD19 beads (Miltenyi, Paris, France). Primary cells were 
cultured in RPMI-1640 supplemented with 10% FCS and 2 
mM glutamine. Human platelets were isolated from citrate 
blood donated by healthy volunteers. Washed platelets were 
cultured in Hepes-buffered saline (HBS, 10 mM Hepes, 150 
mM NaCl, 5 mM KCl, 1 mM MgSO4, pH 7.4).
Chemical
ABT-737, Venclexta™ (ABT-199) and ABT-263 
were obtained from Selleck-Chem. Synthesis of S55746 
is described in the supplemental material and methods.
Fluorescence polarization (FP)
The assays were carried out in black-walled, flat 
bottomed, low binding, 384-well plates in buffer A (10 
mM 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
[HEPES], 150 mM NaCl, 0.05% Tween 20, pH 7.4 and 5% 
DMSO) in the presence of 10 nM Fluorescein-PUMA. Final 
concentrations of MCL-1, BFL-1, BCL-2 and BCL-XL 
proteins were 10, 10, 10 and 20 nM respectively. The assay 
plates were incubated for 2 hours at room temperature and 
the FP was measured on a Synergy 2 reader (Ex. 528 nm, 
Em. 640 nm, Cut-off 510 nm). The binding of increasing 
doses of compound was expressed as a percentage reduction 
in mP compared to the window established between ‘DMSO 
only’ and ‘total inhibition’ control (30 µM PUMA). The 
inhibitory concentrations that gave a 50% reduction in mP 
(IC50) were determined, from 11-point dose response curves, 
in XL-Fit using a 4-Parameter Logistic Model (Sigmoidal 
Dose-Response Model). The KI was subsequently calculated 
as previously described [42].
Surface plasmon resonance (AIS)
The experiments were performed at 30° C in a 
running buffer HBS-EP pH 7.4 (10 mM HEPES pH 7.4, 150 
mM NaCl, 3 mM EDTA, 0.05% P20) supplemented 1 mM 
TCEP, 2% glycerol and 1% DMSO. PUMA BH3 peptide 
was purchased from Biopeptide LLC and immobilized on 
a CM-5 sensor chip. Standard amine coupling protocol of 
Biacore GE Healthcare has been applied with EDC/NHS 
coupling followed by ethanolamine deactivation. A channel 
treated in the same manner but in the absence of peptide 
was used as the reference channel. Compounds were tested 
in double-diluted series of twelve concentrations with top 
concentrations ranging from 20 nM to 2000 nM. Samples 
were preincubated with 1–2 nM BCL-2 in a running buffer 
and injected over the generated surfaces at a flow rate 15 μl/
min for 300 sec. The calibration curve was generated using 
the same procedure but without added compound. Affinity 
evaluations were performed using the Affinity In Solution 
Model of BIAevaluation 2.1 (BIAcore GE Healthcare Bio-
SciencesCorp) software.
Isothermal titration calorimetry (ITC)
The protein was dialyzed prior to use in 2 L of 25 
mM HEPES, 150 mM NaCl, 5% glycerol (v/v), 0.5% 
MTG (v/v) at pH 7.4 for 3 hours at room temperature. 
The protein was dialyzed using a 3.5 K MWCO Slide-A-
Lyzer™ cassette. The protein solution was recovered, spin-
filtered through a 0.22 µM frit. The filtered protein was 
quantified by UV absorbance at 280 nm using an extinction 
coefficient of 36440 M-1cm-1. 500 ml of dialysis buffer was 
retained (remainder used to rinse out SCHOT bottle) and 
degassed for a minimum of 30 mins under vacuum with 
constant stirring. Typically, 50 µM protein was titrated from 
the syringe into the cell containing 5 µM compound. The 
solutions were carefully matched to ensure same solvent and 
buffer conditions were present in both syringe and cell (this 
is to minimize heat of dilution effects).  The final solution 
was the dialysis buffer plus 1% DMSO and 0.05% P20. The 
experiment was performed over 13 injections with stirring 
at 1000 rpm, gain setting low and at 25º C.  Pure water was 
used in the reference cell. The first injection was 0.5 µl with 
a duration of 1 second with a gap of 150 seconds until the 
further 12 injections of 3.05 µl with a duration 6.1 seconds 
and a 240 second interval between injections. Data was 
analyzed using the vendor supplied software, PEAQ-ITC 
Analysis Software. The data model used was the single site 
model. The data shown is the average of 2 or 3 independent 
experiments. For compounds with affinities greater than 10 
nM it is not possible to accurately determine the potency by 
ITC, however the enthalpy and stoichiometry are accurately 
determined. The data shows that each compound binds with 
a 1:1 stoichiometry and with high enthalpies on BCL-2 
demonstrating a highly specific interaction. 
Crystallography
Crystals of the BCL-2 complex with S55746 
were grown using BCL-2 (His6-BCL-2 based on the 
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2W3I construct with additional mutation G118Q) 
at a concentration of 9.4 mg/ml [20 mM Tris buffer 
pH 7.5, 100 mM NaCl, 2 mM DTT, 1% glycerol] by 
the hanging drop vapour diffusion technique. 2 µl of 
protein solution was mixed with 2 µl of crystallization 
reservoir (0.1 M sodium acetate buffer pH 5.25, 20% 
Jeffamine 600, 10% PEG3350) in a hanging drop 
plate. Crystallization was initiated by the addition of 
micro-crystals of the BCL-2/S55748 complex (S55748 
is a methylated version of S55746). The new crystals, 
which grew over 2–3 days, were crushed and used for 
a second micro-seeding of a fresh mixture BCL-2/
S55746 solution and crystallization reservoir. The plate 
was incubated at 284 K and bi-prism crystals appeared 
overnight and grew to a maximum ~50 μm along the 
edge over 4 days. Suitable crystals for data collection 
were flash frozen in liquid nitrogen after cryoprotection 
using crystallization reservoir. The diffraction data was 
collected at the Proximal station, Soleil Synchrotron, at 
wavelength 0.97857 Å using Pilatus-6 M detector. The 
crystal diffracted to 1.39 Å, P212121 space group and 
cell dimensions a = 35.09, b = 46.9, c = 85.04, α,β,γ 
90,90,90 and mosaicity of 0.2 degrees and one molecule 
per asymmetric unit. Several cycles of refinement 
were conducted with Refmac5 software from the ccp4 
package, alternating with manual rebuilding using the 
COOT software package. The final model consisted 
of 144 residues, S55746 ligand and 152 molecules of 
water. S55746 topology restraints were defined using 
the ProDrug software package.
Cell sorting and flow cytometry analysis
CLL cells were exposed for 4 h with S55746 (1, 3, 10, 
30, 100 nM) before analysis of apoptosis using staining with 
AnnexinV-FITC/propodium iodide and flow cytometry. 
EC50 values were calculated using GraphPadPrism (non-
linear fit, sigmoidal dose response, variable slope). Washed 
human platelets were cultured at a final density of 2.5 × 
107/ml and exposed for 3 h with S55746 (3, 10, 30, 100, 
300, 1000, 3000 nM) before staining with CD41-PE (BD) 
and Annexin-FITC and flow cytometry. Mononuclear 
MCL cells were cultured for 24 h in presence or absence of 
S55746 (concentration ranging from 0.1 nM to 100 nM) in 
RPMI supplemented with 10% FCS and 2 mM glutamine. 
Cell death was assessed in the CD19+ primary MCL cells 
by annexinV-FITC staining combined with an analysis of 
altered cellular morphology (lower FCS). Fluorescence was 
analyzed on FACSCalibur. The EC50 value was determined 
by the S55746 concentrations resulting in 50% of annexinV 
positive cells.
RS4;11 cells were treated with the indicated 
compounds for 2h, centrifuged and washed with binding 
buffer (10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl2). Cells 
were incubated with 200 µl of binding buffer containing 
AnnexinV–FITC (Invitrogen) and propidium iodide (PI, 
Sigma) during 15 min at 20° C in the dark. THP-1 cells 
were incubated with 200 µl of binding buffer containing 
AnnexinV–APC (BD Biosciences) and DAPI (Sigma). 
400 µl of binding buffer was added and samples were kept 
at 4° C before cytometric analysis. For each sample, 104 
cells were analyzed by flow cytometry on Epics XL/MCL 
flow cytometer (Beckman Coulter, France). Fluorescence 
was collected at 520 (FITC), 630 nm (PI), 660 nm (APC) 
and 470 (DAPI). Numbers of apoptotic cells (addition of 
primary apoptosis, secondary apoptosis and necrosis) was 
normalized to the total numbers of cells per tubes. 
CellTiter-Glo luminescent cell viability assay
Cells were seeded into 96-well plates and treated at 8 
points with 1:2 serial dilution of compounds. Cell viability 
was assessed and assayed for viability using CellTiter-
Glo reagent (Promega) following the manufacturer’s 
instructions. Plates were read using Tecan luminescence 
plate reader. Results were normalized to the viability of 
cells without compounds (control wells). The IC50 values 
were calculated using nonlinear regression algorithms in 
XCell software.
In vivo xenografts
Experiments were performed in SCID/beige female 
mice from Charles River Laboratories, Massachusetts, 
USA. Animals, approximately 7-8 weeks of age at the 
start of the treatment were allowed to acclimate in animal 
facility with access to food and water ad libitum for 3 
days prior to manipulation. Animals were handled in 
accordance with IACUC regulations and guidelines for 
experiments performed in the USA and with European and 
French regulation for the protection of vertebrate animals 
for experiments performed in France. Animal well-being 
and behavior, including grooming and ambulation were 
monitored at least once a day. General health of mice was 
monitored and mortality recorded daily. Any moribund 
animals were sacrificed.
RS4;11 Acute Lymphoblastic Leukemia cell 
lines was obtained from ATCC. Toledo (Diffuse Large 
B-Cell Lymphoma) human cell lines were obtained 
internally through Bioresources and the Novartis-
Cancer Cell Line Encyclopedia [43]. Cells were free 
of Mycoplasma and murine viral contamination in 
the IMPACT VIII PCR assay panel (IDEXX RADIL, 
IDEXX laboratories INC, Westbrook, ME, USA). 
Cells used for subcutaneous implantation were cultured 
in RPMI plus 10% FBS at 37° C in a humidified 
atmosphere containing 5% carbon dioxide). For 
RS4;11 culture, the medium was also supplemented 
with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/
ml streptomycin, 10 mM Hepes and 4.5 g/L glucose. 
Cells were resuspended in a 1:1 mixture of cold DPBS 
(Dulbecco’s Phosphate-Buffered Saline) and Matrigel™ 
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(Becton-Dickinson #354234) at a concentration of 3 × 107 
cells/ml for Toledo cells, and of 1 × 107 cells/ml for 
RS4;11 cells.
For each experiment, female SCID/beige mice were 
implanted subcutaneously (right axillary region) with 3 × 
106 Toledo or RS4;11 (1 × 106 cells for efficacy studies and 
1 × 107 cells for pharmacodynamics studies) suspended in 
1:1 mixture of cold DPBS and Matrigel™  in a total volume 
of 100 μl. Body weights were recorded and tumors were 
measured with digital calipers twice to three times a 
week . Tumor volume was calculated using the formula: 
length × width2/2. Percent changes in body weights was 
calculated as (BWcurrent - BWinitial)/(BWinitial) × 100. 
Data is presented as percent body weight change from the 
day of treatment initiation.
When tumors reached approximately 200 mm3 
for efficacy studies or 300 mm3 for pharmacodynamic 
studies, mice were randomized. S55746 was formulated in 
PEG300/EtOH/water (40/10/50). ABT-199 was formulated 
in PEG300/EtOH/Phosal (30/10/60). Mice were treated 
via oral gavage at 10 ml/kg with the doses and schedules 
described in the figure.
For pharmacodynamic studies, blood and tumors 
were removed 16 h post dosing and immediately snap-
frozen. Total proteins were extracted from the tumors 
and caspase-3 activity was assessed in triplicate using 
CaspACE® Assay System (Promega). Platelet cell counts 
were determined 16 hours post dosing using Coulter AcT 
diff (Beckman).
For efficacy studies, percent treatment/control (T/C) 
values were calculated using the following formula: %T/C 
= 100 × ΔT/ΔC if ΔT > 0. Regression = 100 × ΔT/Tinitial 
if ΔT < 0 where: T = mean tumor burden of the drug-
treated group on the final day of the study; ΔT = mean 
tumor burden of the drug-treated group on the final day 
of the study – mean tumor burden of the drug-treated 
group on initial day of dosing; Tinitial = mean tumor burden 
of the drug-treated group on initial day of dosing; C = 
mean tumor burden of the control group on the final day 
of the study; and ΔC = mean tumor burden of the control 
group on the final day of the study – mean tumor burden 
of the control group on initial day of dosing. If the tumor 
volume was less than 14 mm3 for more than 3 consecutive 
measurements, animals were considered in complete 
regression (CR).
Statistical analysis
All in vivo data were expressed as mean ± standard 
error of the mean (SEM). Delta tumor volume and body 
weight were used for statistical analysis. Between-group 
comparisons were carried out using the Kruskal-Wallis 
ANOVA followed by a post hoc Dunn’s test or Tukey’s 
test. For all statistical evaluations, the level of significance 
was set at p < 0.05. Significance compared to the vehicle 
control group is reported unless otherwise stated.
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